ARCUTIS BIOTHERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.705 USD | -4.55% |
|
+12.76% | +173.68% |
| May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
| May. 15 | Sector Update: Health Care Stocks Rise Pre-Bell Wednesday | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 160M | Sales 2025 * | 237M | Capitalization | 1.06B |
|---|---|---|---|---|---|
| Net income 2024 * | -189M | Net income 2025 * | -142M | EV / Sales 2024 * | 5.15 x |
| Net cash position 2024 * | 231M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 3.49 x |
| P/E ratio 2024 * |
-5.4
x | P/E ratio 2025 * |
-7.78
x | Employees | 296 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arcutis Biotherapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.37% | ||
| 1 week | +13.78% | ||
| Current month | +9.68% | ||
| 1 month | -9.65% | ||
| 3 months | -1.88% | ||
| 6 months | +367.95% | ||
| Current year | +182.51% |
1 week
7.70
10.13
1 month
7.4710.38
Current year
3.0713.17
1 year
1.7613.17
3 years
1.7629.37
5 years
1.7640.88
10 years
1.7640.88
| Managers | Title | Age | Since |
|---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 55 | 15-12-31 |
Rajvir Madan
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Jay Ramsinghani
COO | Chief Operating Officer | - | 20-05-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Heron
CHM | Chairman | 53 | 16-03-31 |
| Founder | 69 | 16-05-31 | |
Keith Leonard
BRD | Director/Board Member | 62 | 21-09-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.04% | 1,487 M€ | +9.08% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 8.82 | -3.29% | 462 846 |
| 24-05-16 | 9.12 | -1.30% | 4,310,073 |
| 24-05-15 | 9.24 | +13.65% | 13,896,318 |
| 24-05-14 | 8.13 | +1.75% | 4,658,048 |
| 24-05-13 | 7.99 | +1.91% | 2,339,107 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Companyâs pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
9.12
USD
Average target price
18.67
USD
Spread / Average Target
+104.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +182.51% | 1.06B | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.61% | 22.28B | |
| -11.90% | 22.41B | |
| -5.57% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- ARQT Stock
